☆ 4.6 Article

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer

Ying Fan et al.

Summary: This study evaluated the value of ddPCR in detecting MET amplification in non-small cell lung cancer (NSCLC) patients. The results showed a high concordance between ddPCR and FISH in detecting MET amplification, and a good concordance in MET amplification detection in both blood and tissue samples. Moreover, there was no statistical difference between MET amplification and EGFR T790M, but the rate of MET amplification was significantly increased in patients with resistance to third generations of EGFR-TKIs.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of Wnt-beta-catenin-STAT3 signaling

Shunfeng Hu et al.

Summary: PTGDS is highly expressed in DLBCL and correlates with poor prognosis. It promotes cell proliferation in DLBCL, while its inhibitor AT56 has anti-tumor effects in DLBCL therapy.

CELL DEATH AND DIFFERENTIATION (2022)

添加到收藏夹

Review Oncology

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment

Alex Friedlaender et al.

Summary: Classic activating mutations in EGFR and HER2 are predictive of response to targeted therapies, while insertion mutations in exon 20 of either gene are generally less sensitive to treatment. Novel therapeutic strategies are being developed to effectively target tumors driven by these non-classic mutations.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Noninvasive proteomic biomarkers for alcohol-related liver disease

Lili Niu et al.

Summary: This study used mass spectrometry analysis to investigate the liver and plasma proteomics of patients with alcohol-related liver disease. Noninvasive biomarkers associated with early stages of disease progression were identified. Machine learning models revealed that these biomarkers could accurately detect fibrosis and inflammation, and predict future liver-related events and all-cause mortality.

NATURE MEDICINE (2022)

添加到收藏夹

Article Oncology

Multiplex Droplet Digital PCR Assay for Detection of MET and HER2 Genes Amplification in Non-Small Cell Lung Cancer

Igor P. Oscorbin et al.

Summary: Non-small-cell lung cancer (NSCLC) is a common tumor with high mortality and morbidity rate. Alterations in HER2 and MET could lead to resistance to anti-EGFR drugs. Existing methods for detecting HER2 and MET amplifications are time-consuming, and alternative methods are needed. We developed a multiplex droplet digital PCR assay for the simultaneous detection of MET and HER2 amplification in NSCLC samples. The developed assay showed promising results in screening MET and HER2 amplification in NSCLC samples.

CANCERS (2022)

添加到收藏夹

Article Oncology

MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome

Wei Yin et al.

Summary: This study evaluated the correlation of MET expression level with MET copy number gain/amplification, and the MET overexpression with patient's outcome. The study found that the concordance of MET expression and MET copy number gain/amplification was low; high-level of MET expression was associated with inferior outcome, but it was not an independent poor prognostic factor.

CANCERS (2022)

添加到收藏夹

Review Oncology

Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC

Jan Trost Jorgensen et al.

Summary: MET is a receptor tyrosine kinase that plays a significant role in cancer cell progression and is targeted by several drugs under development for the treatment of different cancers. However, the lack of effective biomarkers to select the right patients for treatment may be one of the reasons why relatively few of these drugs have shown sufficient clinical activity and obtained regulatory approval. MET exon 14 skipping mutation and MET amplification detected by FISH are two potential biomarkers, with the former showing sufficient predictive properties and the latter showing promising results in the treatment of NSCLC patients.

CANCERS (2022)

添加到收藏夹

Review Oncology

Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision

Gillianne G. Y. Lai et al.

Summary: Dysregulated MET signaling plays an important role in lung oncogenesis. MET overexpression, gene amplification, or mutation can all lead to MET dysregulation. METex14 is a reliable predictor of response to selective MET tyrosine kinase inhibitors (TKIs), and MET amplification is associated with the response to MET-TKIs. Therefore, the detection methods for METex14, MET amplification, and MET overexpression are crucial, but there are challenges and evidence gaps in their clinical application.

CANCER TREATMENT REVIEWS (2022)

添加到收藏夹

Article Oncology

Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors

James P. Solomon et al.

Summary: This study validated and optimized the utility of next-generation sequencing (NGS) in assessing MET copy number alterations, achieving high concordance, sensitivity, and specificity. MET copy gains and amplifications were found in certain malignancies, with high-level/focal amplification associated with targeted therapy response.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Hematology

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis

Zemin Ren et al.

Summary: Plasma cells in multiple myeloma rely heavily on communication with the bone marrow microenvironment for survival, with specific growth and survival factors being regulated by syndecan-1/HSPGs and their synthesis machinery.

BLOOD (2021)

添加到收藏夹

Review Oncology

Exosome-based liquid biopsies in cancer: opportunities and challenges

W. Yu et al.

Summary: Liquid biopsy in cancer research has seen significant progress, with efforts focused on utilizing circulating tumor cells, circulating tumor DNA, and extracellular vesicles like exosomes. Exosomes, as part of the intercellular communication system, carry tumor-derived materials and can serve as stable biomarkers for early detection and monitoring of cancer.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors

Lun-Xi Peng et al.

Summary: MET amplification identified by FISH remains the optimal biomarker for predicting the efficacy of MET-TKI therapy in NSCLC patients, while the amplification identified by NGS does not show the same predictive ability, especially in distinguishing clinical outcomes. Further exploration is needed on the subtle differences in predicting efficacy by NGS.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development

Abhijit Pal et al.

Summary: This Perspective examines the potential of integrating liquid biopsy analyses into the PhAT, focusing on the use of plasma circulating cell-free tumour DNA and circulating tumour cells as prognostic, predictive, pharmacodynamic, clinical response and resistance biomarkers. The authors also emphasize the importance of analytical validation and clinical qualification in this context.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Prediction and prognostic significance of ALOX12B and PACSIN1 expression in gastric cancer by genome-wide RNA expression and methylation analysis

Zhiping Liu et al.

Summary: The study revealed that the genes ALOX12B and PACSIN1 had higher expression levels in metastasis samples of GC patients, associated with poor survival. These genes may serve as potential biomarkers for metastasis and poor prognosis in GC.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

添加到收藏夹

Editorial Material Biochemistry & Molecular Biology

SnapShot: Clinical proteomics

Yi Zhu et al.

CELL (2021)

添加到收藏夹

Article Oncology

Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Mohamed Eltahir et al.

Summary: Immunotherapy in lung cancer patients leads to varying responses, with some showing higher or lower levels of immune markers in blood samples correlating to better survival. A study evaluated a blood-based test to predict treatment efficacy, finding that certain plasma protein levels could predict response better than traditional PD-L1 scoring. The use of multiplex plasma protein levels as a tool for anti-PD-(L)1 response prediction in NSCLC was supported by the findings, with specific protein signatures identified for response prediction to anti-PD-(L)1 therapy.

CANCERS (2021)

添加到收藏夹

Article Oncology

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Lecia Sequist et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

ALOX12B promotes carcinogenesis in cervical cancer by regulating the PI3K/ERK1 signaling pathway

Tao Jiang et al.

ONCOLOGY LETTERS (2020)

添加到收藏夹

Article Critical Care Medicine

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi-Long Wu et al.

LANCET RESPIRATORY MEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

Michael A. Gillette et al.

CELL (2020)

添加到收藏夹

Review Oncology

MET-dependent solid tumours - molecular diagnosis and targeted therapy

Robin Guo et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy

Satoshi Yamashita et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma

Xian Lin et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

添加到收藏夹

Article Oncology

Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer

Gillianne Gy Lai et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

Robin Guo et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Clinical potential of mass spectrometry-based proteogenomics

Bing Zhang et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy

Henning Reis et al.

CLINICAL LUNG CANCER (2018)

添加到收藏夹

Article Oncology

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas

Xavier Mignard et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib

Geoffrey R. Oxnard et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Revisiting biomarker discovery by plasma proteomics

Philipp E. Geyer et al.

MOLECULAR SYSTEMS BIOLOGY (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia

O. Zimmermannova et al.

ONCOGENE (2017)

添加到收藏夹

Article Oncology

Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

Sinead A. Noonan et al.

JOURNAL OF THORACIC ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer

Anna Li et al.

LUNG CANCER (2015)

添加到收藏夹

Article Oncology

MET Amplification Status in Therapy-Naive Adeno- and Squamous Cell Carcinomas of the Lung

Hans-Ulrich Schildhaus et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Comprehensive molecular profiling of lung adenocarcinoma

Eric A. Collisson et al.

NATURE (2014)

添加到收藏夹

Article Urology & Nephrology

The Impact of Germline Genetic Variations in Hydroxysteroid (17-Beta) Dehydrogenases on Prostate Cancer Outcomes After Prostatectomy

Etienne Audet-Walsh et al.

EUROPEAN UROLOGY (2012)

添加到收藏夹

Article Oncology

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer

Heounjeong Go et al.

JOURNAL OF THORACIC ONCOLOGY (2010)

添加到收藏夹

Article Oncology

Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients

Federico Cappuzzo et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Article Multidisciplinary Sciences

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

Jeffrey A. Engelman et al.

SCIENCE (2007)

添加到收藏夹

Article Pharmacology & Pharmacy

Gefitinib

CR Culy et al.

DRUGS (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.